Casdin Capital as of June 30, 2021
Portfolio Holdings for Casdin Capital
Casdin Capital holds 54 positions in its portfolio as reported in the June 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Invitae (NVTAQ) | 10.4 | $412M | 12M | 33.73 | |
| Biolife Solutions Com New (BLFS) | 8.4 | $331M | 7.4M | 44.51 | |
| Fate Therapeutics (FATE) | 7.5 | $295M | 3.4M | 86.79 | |
| EXACT Sciences Corporation (EXAS) | 7.4 | $293M | 2.4M | 124.31 | |
| Verve Therapeutics (VERV) | 4.6 | $183M | 3.0M | 60.25 | |
| Pacific Biosciences of California (PACB) | 4.4 | $175M | 5.0M | 34.97 | |
| Alnylam Pharmaceuticals (ALNY) | 4.3 | $170M | 1.0M | 169.52 | |
| Blueprint Medicines (BPMC) | 3.5 | $136M | 1.6M | 87.96 | |
| Twist Bioscience Corp (TWST) | 3.4 | $133M | 1.0M | 133.25 | |
| Denali Therapeutics (DNLI) | 3.2 | $126M | 1.6M | 78.44 | |
| Relay Therapeutics (RLAY) | 3.1 | $124M | 3.4M | 36.59 | |
| Agios Pharmaceuticals (AGIO) | 3.0 | $119M | 2.2M | 55.11 | |
| Caredx (CDNA) | 2.8 | $109M | 1.2M | 91.52 | |
| Beam Therapeutics (BEAM) | 2.7 | $105M | 819k | 128.71 | |
| Codexis (CDXS) | 2.5 | $98M | 4.3M | 22.66 | |
| Century Therapeutics (IPSC) | 2.4 | $94M | 3.2M | 29.34 | |
| Singular Genomics Systems In | 1.9 | $74M | 2.7M | 27.48 | |
| Revolution Medicines (RVMD) | 1.9 | $73M | 2.3M | 31.74 | |
| Dermtech Ord ord (DMTKQ) | 1.8 | $73M | 1.7M | 41.57 | |
| Sarepta Therapeutics (SRPT) | 1.7 | $69M | 885k | 77.74 | |
| Adaptive Biotechnologies Cor (ADPT) | 1.5 | $59M | 1.4M | 40.86 | |
| Beigene Sponsored Adr (BGNE) | 1.3 | $52M | 150k | 343.19 | |
| Amyris Com New | 1.2 | $49M | 3.0M | 16.37 | |
| Global Blood Therapeutics In | 1.2 | $46M | 1.3M | 35.02 | |
| Constellation Pharmceticls I | 1.2 | $45M | 1.3M | 33.80 | |
| Generation Bio (GBIO) | 1.1 | $43M | 1.6M | 26.90 | |
| Crispr Therapeutics Namen Akt (CRSP) | 1.1 | $43M | 266k | 161.89 | |
| Alector (ALEC) | 0.9 | $34M | 1.7M | 20.83 | |
| Zai Lab Adr (ZLAB) | 0.9 | $34M | 190k | 176.99 | |
| Magenta Therapeutics | 0.8 | $33M | 3.3M | 9.78 | |
| 23andme Holding Class A Com (ME) | 0.8 | $32M | 2.7M | 11.69 | |
| Allogene Therapeutics (ALLO) | 0.8 | $32M | 1.2M | 26.08 | |
| 4d Molecular Therapeutics In (FDMT) | 0.7 | $27M | 1.1M | 24.08 | |
| Neogenomics Com New (NEO) | 0.6 | $22M | 489k | 45.17 | |
| Monte Rosa Therapeutics (GLUE) | 0.6 | $22M | 961k | 22.70 | |
| Syndax Pharmaceuticals (SNDX) | 0.5 | $21M | 1.2M | 17.17 | |
| Recursion Pharmaceuticals In Cl A (RXRX) | 0.5 | $20M | 548k | 36.50 | |
| 908 Devices (MASS) | 0.4 | $16M | 407k | 38.75 | |
| Orchard Therapeutics Ads | 0.4 | $14M | 3.2M | 4.39 | |
| Kronos Bio (KRON) | 0.4 | $14M | 583k | 23.95 | |
| Fulcrum Therapeutics (FULC) | 0.3 | $12M | 1.2M | 10.48 | |
| Oric Pharmaceuticals (ORIC) | 0.3 | $11M | 602k | 17.69 | |
| Decibel Therapeutics | 0.3 | $10M | 1.2M | 8.60 | |
| Clover Health Investments Com Cl A (CLOV) | 0.2 | $9.7M | 727k | 13.32 | |
| Berkeley Lts | 0.2 | $9.0M | 200k | 44.81 | |
| Alpha Teknova (TKNO) | 0.2 | $7.1M | 300k | 23.73 | |
| Sangamo Biosciences (SGMO) | 0.2 | $6.6M | 550k | 11.97 | |
| Turning Point Therapeutics I | 0.1 | $5.9M | 75k | 78.03 | |
| Nautilus Biotechnology (NAUT) | 0.1 | $5.1M | 500k | 10.10 | |
| Seer Com Cl A (SEER) | 0.1 | $4.9M | 150k | 32.78 | |
| Stoke Therapeutics (STOK) | 0.1 | $4.0M | 120k | 33.66 | |
| Foghorn Therapeutics (FHTX) | 0.1 | $2.3M | 216k | 10.67 | |
| Zymergen | 0.0 | $1.2M | 30k | 40.00 | |
| Sana Biotechnology (SANA) | 0.0 | $1.2M | 60k | 19.67 |
